SynthesisBMJ open2015
Use and safety of azithromycin in neonates: a systematic review.
Synthesis in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03960970 (Azithromycin-based Extended-spectrum Prophylaxis in Scheduled Cesarean Deliveries), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Azithromycin-based Extended-spectrum Prophylaxis in Scheduled Cesarean Deliveries
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Macrolides for the prevention of bronchopulmonary dysplasia in preterm neonates.The Cochrane database of systematic reviews · 2026Pooled it
- Safety of azithromycin in pediatrics: a systematic review and meta-analysis.European journal of clinical pharmacology · 2020Pooled it
- The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT).Pediatric pulmonology · 2025Trial
- Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes.Pediatric research · 2022Trial
- Safety of azithromycin in infants under six months of age in Niger: A community randomized trial.PLoS neglected tropical diseases · 2018Trial
- Postnatal Azithromycin Is Neuroprotective and Anti-Inflammatory in a Piglet Model of Hypoxic-Ischemic Encephalopathy.Stroke · 2026Article
- Risk factors for BPD and relevant nursing models of care to improve outcomes: a narrative review.Frontiers in pediatrics · 2026Review
- Efficacy and safety of azithromycin in preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Review
- [Advances in clinical pharmacotherapy for neonatalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Changes of serum inflammatory markers and immune function in children with bronchial asthma complicated with mycoplasma pneumoniae infection before and after treatment and their clinical significance.Pakistan journal of medical sciences · 2025Article
- Epidemiological characteristics and clinical antibiotic resistance analysis of Ureaplasma urealyticum infection among women and children in southwest China.BMC infectious diseases · 2024Article
- Azithromycin reduces hemoglobin-induced innate neuroimmune activation.Experimental neurology · 2024Article
- Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d'Ivoire.PLOS global public health · 2024Article
- In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.Scientific reports · 2023Article
- Article
- Article
- Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks.Infectious diseases of poverty · 2022Review
- Article
- Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?Frontiers in pediatrics · 2022Review
- Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis.Translational pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify the use and adverse drug reactions associated with azithromycin in neonates.
settingDatabases MEDLINE (1948-August 2015), EMBASE (1980-August 2015) and Pubmed (August 2015) were searched for studies on azithromycin in neonates.
participantsAll studies involving neonates (<28 days old) who have received at least a single dose of azithromycin for which safety was evaluated. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was adverse event (AE) associated with use of azithromycin. Use of azithromycin in neonates was the secondary outcome.
resultsA total of 11 articles involving 473 neonates were identified. 371 AEs were reported. Adverse events were mainly respiratory (358/1000 neonate), neurological (273/1000 neonates) and gastrointestinal (196/1000 neonates) in origin. Azithromycin significantly reduced the risk of bronchopulmonary dysplasia (BPD) in extremely premature neonates (RR=0.83, 95% CI 0.71 to 0.98, p=0.02). There was no significant difference in the incidence of elevated liver enzymes between the azithromycin and placebo group (p=0.76). There were four cases of infantile hypertrophic pyloric stenosis (IHPS).
conclusionsAzithromycin significantly reduces the risk of BPD in preterm neonates. The relationship between azithromycin and IHPS requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.